Výsledky vyhledávání - "Candice L Wellens"

Akademický článek

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

Autor: Sara A Byron, Michael Gartside, Matthew A Powell, Candice L Wellens, Feng Gao, David G Mutch, Paul J Goodfellow, Pamela M Pollock

Publikováno v: PLoS ONE, Vol 7, Iss 2, p e30801 (2012)

Mutations in multiple oncogenes including KRAS, CTNNB1, PIK3CA and FGFR2 have been identified in endometrial cancer. The aim of this study was to provide insight into the clinicopathological features associated with patterns of mutation in these gene

Externí odkaz: https://doaj.org/article/60437408e31345028462a36e68cfd760

Zobrazit plný text záznamu

Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

Publikováno v: Molecular Cancer Research. 7:41-54

We report that 10% of melanoma tumors and cell lines harbor mutations in the fibroblast growth factor receptor 2 (FGFR2) gene. These novel mutations include three truncating mutations and 20 missense mutations occurring at evolutionary conserved resi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::147c9951ecc3754a073faa0438927f31
https://doi.org/10.1158/1541-7786.mcr-08-0021

Zobrazit plný text záznamu

Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation

Autor: Paul J. Goodfellow, Jack B. Keenan, Pamela M. Pollock, Candice L. Wellens, Matthew A. Powell, Michael Gartside, Mary Ann Mallon, Sara A. Byron

Publikováno v: Cancer Research. 68:6902-6907

KRAS activation and PTEN inactivation are frequent events in endometrial tumorigenesis, occurring in 10% to 30% and 26% to 80% of endometrial cancers, respectively. Because we have recently shown activating mutations in fibroblast growth factor recep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eebbce0eb9cd80c121626113bb10d88e
https://doi.org/10.1158/0008-5472.can-08-0770

Zobrazit plný text záznamu

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

Autor: Kenichi Nomoto, Sara A. Byron, John Wang, Candice L. Wellens, Jiayi Wu, Andreas Wortmann, David Loch, Pamela M. Pollock

Publikováno v: BMC Molecular Cancer
Molecular Cancer, Vol 11, Iss 1, p 75 (2012)
Molecular Cancer

Background Melanoma is the most lethal form of skin cancer, but recent advances in molecularly targeted agents against the Ras/Raf/MAPK pathway demonstrate promise as effective therapies. Despite these advances, resistance remains an issue, as illust

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47af890de80ae60acfe19d12ee2dd9eb
https://doi.org/10.1186/1476-4598-11-75

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání